Company History - from formation until now............................

Senexis was originally formed in 2001 to develop a series of patents on a peptide-based amyloid aggregation inhibitors. The Company's original founders independently developed the inhibitors in Manchester and Cambridge but Senexis was then established in Prof. Andrew Doig's academic laboratory at UMIST in Manchester. A picture of the location of that first laboratory in Jackson's Mill at UMIST (now the University of Manchester) is shown to the right. Dr Mark Treherne joined the Company as Chief Executive, when it raised £1.4 million seed funding in November 2002 from BTG plc and the Wellcome Trust Limited (formerly Catalyst BioMedica Limited).

Senexis moved from academia to the Babraham Research Campus, near Cambridge in 2004, where it continued to build an experienced management team that is capable of taking compounds into clinical development, particularly when Dr Chris Moyses joined as Chairman and Dr David Scopes joined as Chief Scientific Officer. Subsequently, Senexis raised an additional £1 million early in 2006, followed by a further £0.8 million during 2007 to further develop its broad portfolio of potent and novel "small molecule" compounds, which are active in several established models of Alzheimer's disease. Drug-like small molecules are the focus of the Company's activities due to their oral bioavailability. In early 2008, Senexis raised a further £2.9 million to accelerate the Company's successful small-molecule aggregation inhibitor programmes. To date, Senexis has raised £6.1 million.

Some pictures of the Babraham Research Campus are shown below: